How Does Cagrilintide Work? Mechanism of Action, Per the Research

This page is for educational purposes only and is not medical advice; consult a licensed physician or prescribing clinician about any question concerning investigational or prescription medicines. Cagrilintide is described in the literature cited here as an investigational prescription-pathway medicine studied in company-sponsored clinical trials, not as a consumer product, and nothing below describes how it should be used.

The short answer

Cagrilintide is a chemically modified, long-acting version of amylin, a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. A review of cagrilintide pharmacology described it as a long-acting amylin analogue developed for the treatment of obesity, designed for once-weekly administration (PMID 36883831). A review of amylin as a neuroendocrine hormone explained that native amylin acts through receptors formed by the calcitonin receptor in combination with receptor activity-modifying proteins, and that this signalling contributes to the control of food intake and glucose handling (PMID 38338796). In other words, the proposed mechanism is hormonal mimicry: the molecule engages a satiation-signalling system that the body already uses after a meal.

Where cagrilintide came from: the amylin story

A historical account of amylin research described how the peptide was identified in pancreatic islet amyloid and subsequently characterised as a beta-cell hormone co-secreted with insulin, with physiological roles in meal-related signalling (PMID 35183619). That same account traced the development path from the native hormone to pramlintide, a soluble, non-aggregating analogue created because human amylin itself is prone to forming fibrils (PMID 35183619). A pharmacology handbook chapter on drugs for treating obesity similarly placed amylin analogues among the centrally acting agents studied for body-weight regulation (PMID 34783910).

A review of amylin analogues for obesity without diabetes described cagrilintide as a lipidised, long-acting analogue whose structural modifications were intended to improve solubility and extend the duration of action relative to earlier short-acting amylin analogues (PMID 39317404). The same review situated cagrilintide within a broader class of amylin-receptor–directed candidates under clinical investigation (PMID 39317404).

Receptor targets: the calcitonin receptor family

Amylin does not have a single dedicated receptor protein. The amylin review explained that amylin receptors are heterodimers assembled from the calcitonin receptor and receptor activity-modifying proteins (RAMP1, RAMP2 and RAMP3), generating the AMY1, AMY2 and AMY3 receptor subtypes, and that signalling through these complexes underlies amylin's effects on satiation and glucose regulation (PMID 38338796). Because the calcitonin receptor is the shared backbone, analogues in this class can show activity at both amylin receptors and the calcitonin receptor itself.

The cagrilintide review characterised the molecule as a non-selective amylin analogue with activity across amylin and calcitonin receptor targets, in contrast with compounds engineered for narrower receptor selectivity (PMID 36883831). A discovery-to-clinic report on eloralintide, a different investigational peptide, described that molecule as a selective amylin receptor agonist, and the researchers presented preclinical characterisation alongside early clinical proof-of-concept data (PMID 41109426). That contrast is the clearest way to frame an open question in the field: whether broader calcitonin-receptor engagement adds benefit, adds tolerability burden, or both.

Why the molecule lasts a week

The cagrilintide review attributed the extended half-life to acylation — attachment of a lipid side chain that promotes albumin binding and slows clearance — which supported once-weekly administration in clinical studies (PMID 36883831). The amylin-analogue review made the same general point for the long-acting class: structural lipidation was the engineering step that moved amylin pharmacology from multiple daily injections toward weekly dosing intervals in trials (PMID 39317404).

Downstream physiology described in the literature

The amylin review described amylin signalling in the hindbrain — particularly the area postrema and nucleus tractus solitarius, regions outside the tight blood–brain barrier — as the route by which the hormone contributes to meal-ending satiation signals (PMID 38338796). The same review reported that amylin's physiological actions include slowing of gastric emptying and suppression of postprandial glucagon secretion, both of which influence post-meal glucose excursions (PMID 38338796). The amylin-analogue review described reduced food intake and enhanced satiation as the mechanistic basis proposed for body-weight effects of analogues in this class (PMID 39317404).

A 2026 review of novel medications for type 2 diabetes and obesity grouped amylin analogues with incretin-based agents as appetite-regulating therapies acting on central and gastrointestinal pathways (PMID 41054801). A clinical review of weight-management treatment likewise listed amylin-receptor agonists among the pharmacological options under development alongside established incretin therapies (PMID 40865172).

Established mechanism versus proposed mechanism

Two caveats belong with that table. First, reviews that describe leptin-sensitising effects of amylin draw heavily on preclinical rodent work, and those reviews framed the translation to humans as unresolved (PMID 38338796; PMID 39317404). Second, receptor-selectivity questions remain proposed rather than settled: the eloralintide report presented selective amylin-receptor agonism as a design hypothesis tested from discovery through early clinical proof of concept, not as a demonstrated superiority over non-selective analogues (PMID 41109426).

How the mechanism showed up in clinical trials

A multicentre, randomised, double-blind, placebo-controlled and active-controlled phase 2 dose-finding trial evaluated once-weekly cagrilintide at 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg and 4.5 mg against placebo and against liraglutide 3.0 mg over 26 weeks in people with overweight and obesity, and the researchers reported greater reductions in body weight with cagrilintide than with placebo across the dose range (PMID 34798060). That dose–response pattern is the clinical signature most often read as consistent with the proposed satiation mechanism, although the study measured weight and tolerability endpoints rather than receptor-level activity (PMID 34798060).

A separate multicentre, randomised, double-blind, active-controlled phase 2 trial examined once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg in people with type 2 diabetes, and the researchers reported glycaemic and body-weight outcomes for the combination relative to the active comparator arms (PMID 37364590). The mechanistic rationale for pairing the two is complementary signalling: a network meta-analysis of GLP-1 receptor agonists described that class as acting on glycaemic control, body weight and lipid parameters in type 2 diabetes (PMID 38286487), while amylin pharmacology operates through the calcitonin-receptor family rather than the GLP-1 receptor (PMID 38338796).

A 2026 review of obesity medications beyond weight loss discussed multisystem effects of this broader therapeutic area, including cardiometabolic outcomes studied across agents (PMID 42208956). A review of weight-management treatment placed combination amylin–incretin approaches among the strategies being tested to increase the magnitude of weight reduction achievable with pharmacotherapy (PMID 40865172).

Tolerability in Trials: What Studies Report

Mechanism and side-effect profile are linked for this class, because slowed gastric emptying and hindbrain signalling are also the pathways through which nausea arises. In the phase 2 dose-finding trial, the researchers reported gastrointestinal adverse events, including nausea, as among the most common adverse events observed with cagrilintide, and also reported injection-site reactions (PMID 34798060). In the type 2 diabetes co-administration trial, the researchers reported that gastrointestinal adverse events were the most frequently observed adverse events across treatment arms (PMID 37364590). The amylin-analogue review similarly described gastrointestinal tolerability as the principal safety consideration discussed for this class (PMID 39317404). Adverse-event frequencies in trials reflect those trial populations and protocols and are not predictions for any individual.

What is still unsettled

• Receptor contribution. How much of cagrilintide's effect derives from amylin receptors versus the calcitonin receptor has not been resolved in human studies; selective agonists were developed in part to probe that question (PMID 41109426).
• Leptin interaction. Reviews described amylin–leptin interaction as a proposed mechanism grounded largely in preclinical work (PMID 38338796).
• Long-term outcomes. The published cagrilintide trials cited here were phase 2 studies with defined durations and endpoints (PMID 34798060; PMID 37364590), and broader multisystem outcome questions for obesity pharmacotherapy were discussed as an evolving evidence base (PMID 42208956).

Regulatory and clinical framing

Cagrilintide is discussed throughout the cited literature as an investigational agent evaluated in clinical trials rather than an established approved therapy, with reviews describing it within the development pipeline for obesity and type 2 diabetes (PMID 36883831; PMID 41054801). Approval status and labelling differ by country and change over time. Any question about whether a medicine in this class is appropriate, available or safe for a particular person belongs with a licensed prescribing clinician, not with a summary page.

Related reading

For a broader overview of the molecule, its development history and the trials discussed above, see the PeptideU cagrilintide overview.

References

• Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity (Cardiology in Review, 2024)
• Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity (International Journal of Molecular Sciences, 2024)
• Amylin analogs for the treatment of obesity without diabetes: present and future (Expert Review of Clinical Pharmacology, 2024)
• Creating the amylin story (Appetite, 2022)
• Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (Lancet, 2021)
• Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (Lancet, 2023)
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (BMJ, 2024)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Weight management treatment in obesity (Medicina Clinica, 2025)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)